Top Tweets for #Pomalyst

HemOnc Today @HemOncToday

5 months ago

🩸 Pomalidomide conferred durable control of nosebleeds in hereditary hemorrhagic telangiectasia, per data in @BloodPortfolio. #Pomalyst could be a long-term therapeutic option for some patients with #HHT. @BMSNews @CureHHT https://t.co/ZUNpp9lPcN

0

5

1

0

90

jojoabab @jojoabab1

9 months ago

@FDAOncology However, the Danish Medicines Council @LMSTdk has recommended to not use Lenalidomide at all for any age. So the drugs that are lethal are #Pomalyst #Pomalidomide #Revlimid #Lenalidomide #IMiD and they are manufactured by Celgene and the Bristol Myers Squibb $BMY from USA.

1

3

0

0

134

jojoabab @jojoabab1

9 months ago

#MultipleMyelomaAwareness @myeloma_today WARNING: #Pomalyst #Pomalidomide #Revlimid #Lenalidomide #IMiD are lethal for patient with a biological age older than 65 years. You have to use https://t.co/N6hxy2tVMb in order to read this Swedish article. https://t.co/Eetd5FjQfW

1

5

1

0

195

Robert Z. Orlowski @Myeloma_Doc

almost 4 years ago

#Myeloma Paper of the Day: Loss of COP9-signalosome genes at 2q37 may be associated with #Revlimid and #Pomalyst resistance in multiple #myeloma: https://t.co/QA4MJM1IS3. #mmsm

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Loss of COP9-signalosome genes at 2q37 may be associated with #Revlimid and #Pomalyst resistance in multiple #myeloma: https://t.co/QA4MJM1IS3. #mmsm https://t.co/E2FoR9t1yB

0

3

4

1

0

Robert Z. Orlowski @Myeloma_Doc

over 4 years ago

#Myeloma Paper of the Day (1/2): Phase 3 OCEAN study comparing #Pepaxto/dex to or #Pomalyst/dex for patients with #myeloma refractory to #Revlimid shows better PFS but significantly worse OS (19.8 months vs. 25.0 months): https://t.co/d5wN4SsYsl. Please see 2/2 on this paper.

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day (1/2): Phase 3 OCEAN study comparing #Pepaxto/dex to or #Pomalyst/dex for patients with #myeloma refractory to #Revlimid shows better PFS but significantly worse OS (19.8 months vs. 25.0 months): https://t.co/d5wN4SsYsl. Please see 2/2 on this paper. https://t.co/vNXczuyUNW$

1

12

5

1

0

Robert Z. Orlowski @Myeloma_Doc

over 4 years ago

Best of luck always. What other drugs are you taking in addition to #Pomalyst?

Nicholi @Nicholi_Avery

over 4 years ago

@Phari @Myeloma_Doc @Transplant_Doc starting pomolyst.. wish me luck..

0

1

0

0

0

0

1

0

0

0

Robert Z. Orlowski @Myeloma_Doc

almost 5 years ago

#Myeloma Paper of the Day: Subanalysis of OPTIMISMM trial finds nice benefit of #Pomalyst/#Velcade/dex at first relapse in #Revlimid-pretreated #myeloma (median PFS 22.0 vs 13.1 months; P = 0.0258): https://t.co/I55FRcB7r5. Would a #Darzalex-based regimen do better though?

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Subanalysis of OPTIMISMM trial finds nice benefit of #Pomalyst/#Velcade/dex at first relapse in #Revlimid-pretreated #myeloma (median PFS 22.0 vs 13.1 months; P = 0.0258): https://t.co/I55FRcB7r5. Would a #Darzalex-based regimen do better though? https://t.co/zwRUoFbrkt

0

23

5

2

0

Evaluate Japan @EvaluateJP

almost 5 years ago

再検討の結果、#Oncopeptides 社の #多発性骨髄腫治療薬 #Pepaxto は、無増悪生存期間で #BMS 社 #Pomalyst を上回った。しかし、全生存期間では下回り、治験が中断されており、承認された適応症を含むプログラム全体に悪影響を及ぼしかねない状況にある。 https://t.co/dzaea5rFSa #エバリュエート

EvaluateJP's tweet photo. 再検討の結果、#Oncopeptides 社の #多発性骨髄腫治療薬 #Pepaxto は、無増悪生存期間で #BMS 社 #Pomalyst を上回った。しかし、全生存期間では下回り、治験が中断されており、承認された適応症を含むプログラム全体に悪影響を及ぼしかねない状況にある。
https://t.co/dzaea5rFSa
#エバリュエート https://t.co/ByVcdYSCB5

0

3

3

0

0

Robert Z. Orlowski @Myeloma_Doc

about 5 years ago

#Myeloma Paper of the Day: APOLLO study comparing #Darzalex/#Pomalyst/dex to #Pomalyst/dex finds triplet is superior in previously treated #myeloma setting with median PFS of 12.4 months vs. 6.9 months https://t.co/6H0SUssIqz

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: APOLLO study comparing #Darzalex/#Pomalyst/dex to #Pomalyst/dex finds triplet is superior in previously treated #myeloma setting with median PFS of 12.4 months vs. 6.9 months https://t.co/6H0SUssIqz https://t.co/5NYIebR6R9

0

5

1

0

0

Robert Z. Orlowski @Myeloma_Doc

about 5 years ago

#Myeloma Paper of the Day: Subgroup analysis of ICARIA-MM trial in relapsed/refractory #myeloma patients with high-risk cytogenetics finds benefit for #Sarclisa/#Pomalyst/dex, especially for those with 1q21 amplification. https://t.co/GSAsqRNt6z

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Subgroup analysis of ICARIA-MM trial in relapsed/refractory #myeloma patients with high-risk cytogenetics finds benefit for #Sarclisa/#Pomalyst/dex, especially for those with 1q21 amplification. https://t.co/GSAsqRNt6z https://t.co/6C7z1HlKYO$

0

7

2

0

0

Robert Z. Orlowski @Myeloma_Doc

over 5 years ago

#Myeloma Paper of the Day: #Sarclisa plus #Pomalyst and dex shows consistent benefits in key patient subgroups with relapsed/refractory #myeloma. https://t.co/RluIkUFdFd

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: #Sarclisa plus #Pomalyst and dex shows consistent benefits in key patient subgroups with relapsed/refractory #myeloma. https://t.co/RluIkUFdFd https://t.co/z08Cqtnm0P$

0

7

2

0

0

Yelak Biru @NorthTxMSG

over 6 years ago

If you’re on #Revlimid #pomalyst or #emplicity and your job or insurance is impacted by #COVID19 @bmsnwws may be able to provide you free medication. 👇

Bristol Myers Squibb @bmsnews

over 6 years ago

During this unprecedented time, if you are a BMS patient in the U.S. and lost your job and health insurance due to the COVID-19 pandemic, we will provide our medicines at no cost. Call 1-800-721-8909.

bmsnews's tweet photo. During this unprecedented time, if you are a BMS patient in the U.S. and lost your job and health insurance due to the COVID-19 pandemic, we will provide our medicines at no cost. Call 1-800-721-8909.

7

215

114

5

0

2

16

6

0

0

Robert Z. Orlowski @Myeloma_Doc

over 7 years ago

All-oral regimen of Selinexor with #Pomalyst/dex shows clinical activity with an ORR of 55% in #Pomalyst-naive patients with heavily pre-treated #myeloma: https://t.co/LnCUMX1rAj. #ASH18

Myeloma_Doc's tweet photo. All-oral regimen of Selinexor with #Pomalyst/dex shows clinical activity with an ORR of 55% in #Pomalyst-naive patients with heavily pre-treated #myeloma: https://t.co/LnCUMX1rAj. #ASH18 https://t.co/bq9BD9SvqO

0

2

3

0

0

over 7 years ago

$CELG #Pomalyst #ASH18

Robert Z. Orlowski @Myeloma_Doc

over 7 years ago

ELOQUENT-3: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Previously Treated Multiple Myeloma - The ASCO Post https://t.co/KbhzS8IFF1 #mmsm

0

2

0

0

0

0

1

0

0

0

Robert Z. Orlowski @Myeloma_Doc

over 7 years ago

Phase 2 trial demonstrates that #Kyprolis/#Pomalyst/dex is a feasible, effective and safe triple drug regimen in relapsed/refractory #myeloma patients who have been previously treated and/or are refractory to #Velcade and refractory to #Revlimid: https://t.co/TJepcQXqSf. #ASH18

$Myeloma_Doc's tweet photo. Phase 2 trial demonstrates that #Kyprolis/#Pomalyst/dex is a feasible, effective and safe triple drug regimen in relapsed/refractory #myeloma patients who have been previously treated and/or are refractory to #Velcade and refractory to #Revlimid: https://t.co/TJepcQXqSf. #ASH18 https://t.co/nZjMPaOTnP$

0

2

2

0

0

Robert Z. Orlowski @Myeloma_Doc

over 7 years ago

#Pomalyst inhibits PD-L1 expression on tumor cells to promote cytotoxic T lymphocyte activity in vitro, and suppresses PD-L1 on antigen-presenting cells to prevent peptide-induced T cell tolerance, which has implications for #myeloma immunotherapy: https://t.co/fa0CQCHz43.

Myeloma_Doc's tweet photo. #Pomalyst inhibits PD-L1 expression on tumor cells to promote cytotoxic T lymphocyte activity in vitro, and suppresses PD-L1 on antigen-presenting cells to prevent peptide-induced T cell tolerance, which has implications for #myeloma immunotherapy: https://t.co/fa0CQCHz43. https://t.co/rMu9EhCPu8

0

4

3

0

0

Robert Z. Orlowski @Myeloma_Doc

almost 8 years ago

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. - PubMed - NCBI https://t.co/VJkEnlINki #pomalyst

0

2

0

0

0

Robert Z. Orlowski @Myeloma_Doc

almost 8 years ago

Homobifunctional, so-called Homo-PROTACs with two #Pomalyst molecules can induce directed ubiquitination and degradation of Cereblon without degradation of IKZF1 and IKZF3 & antagonize effects of #Pomalyst on #myeloma models: https://t.co/n96Mykr0fw.

Myeloma_Doc's tweet photo. Homobifunctional, so-called Homo-PROTACs with two #Pomalyst molecules can induce directed ubiquitination and degradation of Cereblon without degradation of IKZF1 and IKZF3 & antagonize effects of #Pomalyst on #myeloma models: https://t.co/n96Mykr0fw. https://t.co/1MrLExhD3G

0

2

0

0

0

Robert Z. Orlowski @Myeloma_Doc

almost 8 years ago

Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. - PubMed - NCBI https://t.co/hxmJdcqPxf #pomalyst

0

3

2

0

0

Robert Z. Orlowski @Myeloma_Doc

almost 8 years ago

Study of real world outcomes of #Pomalyst for treatment of relapsed light chain #amyloidosis finds deep responses (VGPR or better) are seen in only a third of all patients and combination therapy needs to be explored: https://t.co/2VZA55FSJb.

Myeloma_Doc's tweet photo. Study of real world outcomes of #Pomalyst for treatment of relapsed light chain #amyloidosis finds deep responses (VGPR or better) are seen in only a third of all patients and combination therapy needs to be explored: https://t.co/2VZA55FSJb. https://t.co/2mgHC2NWFM

0

2

1

0

0

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users